Live
Sun Pharmaceutical Industries has said that the US heath regulator has accepted biologics licence application (BLA) for tildrakizumab for the treatment of psoriasis.
Sun Pharma has said in a regulatory filing that “The FDA filing acceptance follows the acceptance of the regulatory filing of tildrakizumab by the European Medicines Agency (EMA) in March 2017. Tildrakizumab is an investigational IL-23p 19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis.”
Abhay Gandhi, Sun Pharma CEO-North America Business has said that “The acceptance of the regulatory filing by the US FDA marks a significant milestone as we seek to advance for tildrakizumab as a potential new treatment option for people who continue to struggle everyday with the chronic nature of psoriasis.”
